Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-2641585/ VELCADE/ Dexamethasone · 1 trial · 1 indication
Based on the safety analysis of all cohorts using the patients-treated population
| Arm | Type | Description |
|---|---|---|
| 001 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| JNJ-2641585 / VELCADE / Dexamethasone | DRUG | JNJ-26481585: type=range, unit=mg, number=6 to 12, form=capsules, route=oral use, on Days 1, 3, and 5 of each week. VELCADE: type=exact, unit=mg/m2, number=1.3, form=powder for solution for injection, route=subcutaneous use, on Days 1, 4, 8, and 11 of each 21-day cycle (Cycles 1 to 8) and on Days 1, 8, 15, and 22 of each 35-day cycle (Cycles 9-11). Dexamethasone: type=exact, unit=mg, number=20, form=tablets, route=oral use, on the day of and after VELCADE. |
Inclusion Criteria: * Eastern Cooperative Oncology Group (ECOG) Performance status score 0-2 * Measurable or secretory multiple myeloma * Relapse or progression of myeloma following prior systemic antineoplastic therapy * Pretreatment clinical laboratory values meeting protocol-specified criteria *...
Top 20 of 25 competitors
JNJ-2641585 is an investigational small molecule being studied in combination with VELCADE (bortezomib) and dexamethasone for the treatment of relapsed multiple myeloma. It is in Phase 1 clinical development and has not been approved by the FDA.
JNJ-2641585 is a histone deacetylase inhibitor (HDACi). It works by inhibiting histone deacetylase enzymes, which play a role in gene expression and cancer cell growth. This mechanism is being explored in combination with other agents for multiple myeloma.
JNJ-2641585 is being developed by Johnson & Johnson, which trades under the ticker symbol JNJ on the New York Stock Exchange. The company is conducting clinical trials to evaluate the drug in combination with VELCADE and dexamethasone for multiple myeloma.
JNJ-2641585 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The Phase 1 trial has been completed, and the drug is no longer in active clinical trials.
JNJ-2641585 has been studied in one completed Phase 1 clinical trial, identified as NCT01464112. This trial was a dose escalation study evaluating JNJ-2641585 in combination with VELCADE (bortezomib) and dexamethasone in patients with relapsed multiple myeloma. The trial enrolled 18 participants in France.
No, JNJ-2641585 is not the same as VELCADE. VELCADE (bortezomib) is a proteasome inhibitor, while JNJ-2641585 is a histone deacetylase inhibitor. In the clinical trial, JNJ-2641585 was studied in combination with VELCADE and dexamethasone for multiple myeloma.